Acrivon Therapeutics, Inc. financial data

Symbol
ACRV on Nasdaq
Industry
Pharmaceutical Preparations
Location
480 Arsenal Way, Suite 100, Watertown, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.27K % -34.8%
Debt-to-equity 9.64 % +34.6%
Return On Equity -48 % -48%
Return On Assets -43.7 % -44.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.1M shares +40.3%
Common Stock, Shares, Outstanding 31.1M shares +40.8%
Common Stock, Value, Issued 31K USD +40.9%
Weighted Average Number of Shares Outstanding, Basic 38.1M shares +72.6%
Weighted Average Number of Shares Outstanding, Diluted 38.1M shares +72.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 60.8M USD +83.7%
General and Administrative Expense 24.5M USD +6.92%
Operating Income (Loss) -85.3M USD -52.3%
Nonoperating Income (Expense) 2.7M USD +61.5%
Net Income (Loss) Attributable to Parent -77M USD -53.8%
Earnings Per Share, Basic -2.71 USD/shares -187%
Earnings Per Share, Diluted -2.71 USD/shares -187%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.4M USD +45.4%
Assets, Current 189M USD +30.8%
Property, Plant and Equipment, Net 4.67M USD +133%
Operating Lease, Right-of-Use Asset 3.8M USD -9.29%
Other Assets, Noncurrent 1.18M USD
Assets 215M USD +42.1%
Accounts Payable, Current 1.51M USD +0.13%
Liabilities, Current 14.8M USD +59.4%
Operating Lease, Liability, Noncurrent 2.97M USD -18.4%
Liabilities 17.8M USD +37.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 782K USD
Retained Earnings (Accumulated Deficit) -174M USD -79.2%
Stockholders' Equity Attributable to Parent 197M USD +42.5%
Liabilities and Equity 215M USD +42.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.1M USD -50.4%
Net Cash Provided by (Used in) Financing Activities -172K USD
Net Cash Provided by (Used in) Investing Activities 5.85M USD -37.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 31.1M shares +40.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4M USD -462%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.6M USD +44.1%
Deferred Tax Assets, Valuation Allowance 31.8M USD +118%
Deferred Tax Assets, Gross 33.3M USD +104%
Operating Lease, Liability 4.01M USD -9.21%
Depreciation 935K USD +111%
Payments to Acquire Property, Plant, and Equipment 815K USD +3160%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -75.9M USD -50.9%
Lessee, Operating Lease, Liability, to be Paid 4.6M USD -12.6%
Property, Plant and Equipment, Gross 6.33M USD +125%
Operating Lease, Liability, Current 1.04M USD +34%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.33M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.34M USD +21.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 591K USD -30.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.21M USD +3.78%
Deferred Tax Assets, Operating Loss Carryforwards 9.4M USD +53.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 404K USD -66.3%
Operating Lease, Payments 300K USD 0%
Additional Paid in Capital 370M USD +57.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.53M USD -14.5%
Share-based Payment Arrangement, Expense 13.6M USD +33.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%